EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE

6728 reported adverse events

Drug classes: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE:

# Side effect Count
0 BONE DENSITY DECREASED 3560
1 RENAL INJURY 2967
2 SKELETAL INJURY 2781
3 TOOTH LOSS 2009
4 CHRONIC KIDNEY DISEASE 1997
5 TOOTH INJURY 1982
6 RENAL FAILURE 1624
7 BONE LOSS 1571
8 OSTEONECROSIS 1521
9 MULTIPLE FRACTURES 1520
See all common reactions for EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE

EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 TOOTH INJURY 1982 0.4561
1 NEONATAL METABOLIC BONE DISEASE 1 0.3333
2 SKELETAL INJURY 2781 0.2686
3 HERPES SIMPLEX VIRUS URETHRITIS 1 0.2500
4 INADEQUATE HOUSING 1 0.1429
5 CREATININE URINE 1 0.1429
6 CLEFT LIP REPAIR 1 0.1250
7 BONE DEMINERALISATION 124 0.1171
8 BONE DENSITY DECREASED 3560 0.1135
9 BONE LOSS 1571 0.1044
See all enriched reactions for EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE